Meldungen zum Thema Medizin, Gesundheit

Folgen
Keine Meldung zum Thema Medizin, Gesundheit mehr verpassen.
Filtern
  • 16.07.2025 – 08:00

    Schweizerischer Nationalfonds / Fonds national suisse

    Tackling antibiotic resistance by capturing bacteria

    Bern (ots) - Rapidly identifying certain bacteria allows antibiotic treatments to be optimised. A team from the University of Zurich, supported by the SNSF, has developed molecules to detect and capture certain species. The discovery of antibiotics revolutionised medicine in the 20th century, saving countless lives. However, the emergence of resistant bacteria has quickly become a new challenge. One key factor in tackling ...

  • 17.06.2025 – 13:31

    Isomorphic Labs

    Isomorphic Labs appoints Dr. Ben Wolf as Chief Medical Officer and establishes US Presence

    London and Boston (ots/PRNewswire) - Precision oncology leader joins world-class team as company enters next phase of translating AI-driven drug discovery into life-changing medicines. Isomorphic Labs, the AI-first drug discovery company, has announced the appointment of Ben B. Wolf, M.D., Ph.D., as Chief Medical Officer. Dr. Wolf will be based in the company's newly ...

  • 17.06.2025 – 09:02

    MedHub; Terumo

    MedHub-AI and Terumo partner to market AI-based FFR in Japan

    Tel Aviv, Israel (ots/PRNewswire) - MedHub-AI, pioneer of AI-based FFR "AutocathFFR" software, today announced a distribution agreement with Terumo Corporation to bring AutocathFFR®, its groundbreaking AI-powered Software as a Medical Device (SaMD), to the Japanese market. This partnership marks a new era in coronary physiology assessment where AI technology delivers superior confidence, reproducibility, and clinical ...

  • 16.06.2025 – 13:40

    Innovative Molecules GmbH

    Innovative Molecules Completes Enrollment of Phase 1b Clinical Trial of IM-250

    Munich (ots/PRNewswire) - Innovative Molecules GmbH Announces Completion of Phase 1b Enrollment for IM-250 in Genital Herpes Clinical Trial Innovative Molecules GmbH today announced the completion of enrollment in the Phase 1b portion of its ongoing Phase 1b/2a clinical trial evaluating IM-250, a next-generation helicase-primase inhibitor targeting herpes simplex virus ...

  • 10.06.2025 – 16:38

    Eidgenössisches Nuklearsicherheitsinspektorat ENSI

    Radiation Protection Report 2024: All Legal Limits Met

    Brugg (ots) - Swiss nuclear installations met all legal radiation protection limits according to ENSI's Radiation Protection Report 2024. Nuclear installation operators have implemented legally compliant and appropriate radiation protection during all operating phases. ENSI also did not detect any increase in local dose rates in the vicinity that could be traced back to emissions from the nuclear installations. Personal ...

  • 06.05.2025 – 15:17

    Healthcare Holding Schweiz AG

    Healthcare Holding Switzerland Acquires Aestheticbedarf

    Baar, Switzerland (ots/PRNewswire) - Healthcare Holding Schweiz AG, a leading provider of services and distributor of medical technology in Switzerland, has expanded its portfolio with the acquisition of Aestheticbedarf AG. Healthcare Holding Schweiz is managed by Winterberg Advisory GmbH. Healthcare Holding Schweiz AG has successfully closed the acquisition of Aestheticbedarf AG, headquartered in Affoltern, an ...

  • 30.04.2025 – 10:09

    Healthcare Holding Schweiz AG

    Healthcare Holding Switzerland Acquires CDP Swiss

    Baar, Switzerland (ots/PRNewswire) - Healthcare Holding Schweiz AG, a leading provider of services and distributor of medical technology in Switzerland, has expanded its portfolio by acquiring CDP Swiss AG and CDP Austria GmbH. Healthcare Holding Schweiz is managed by Winterberg Advisory GmbH. Healthcare Holding Schweiz AG has successfully closed the acquisition of CDP Swiss AG, based in Affoltern, and its subsidiary, CDP ...

  • 29.04.2025 – 09:01

    Acousia Therapeutics GmbH

    Acousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR Study

    Tübingen, Germany (ots) - Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy. Cisplatin is a cornerstone in modern oncology and ...

  • 28.04.2025 – 11:32

    Scantox A/S

    Annual Report 2024 released by Scantox Group

    Ejby, Denmark (ots/PRNewswire) - Scantox Group has released their 2024 Annual Report today. It highlights the many activities the company has done over the year to shape the future of a business that in so many ways contribute to improve lives worldwide through the development of new drugs and treatments. "Our 2024 result shows high profitable growth from transformational acquisitions. We are very pleased with these ...

  • 07.04.2025 – 09:00

    Immunity Pharma

    Immunity Pharma Presents New Data Supporting the Efficacy of IPL344 in ALS

    Jerusalem (ots/PRNewswire) - - Results from phase 2a trial in ALS patients were published in Muscle and Nerve. - Statistically significant 58% to 64% slower ALSFRS-R progression rate in IPL344-treated patients compared to the matched PRO-ACT records. - NfL was reduced by 27% for patients treated for at least two months. - Unadjusted median survival for participants in ...

  • 31.03.2025 – 13:28

    Isomorphic Labs

    Isomorphic Labs announces $600 million funding to further develop its next-generation AI drug design engine and advance therapeutic programs into the clinic

    London (ots/PRNewswire) - Isomorphic Labs will utilise the funding to further power its AI drug design engine through frontier AI research and development and to scale and progress its drug candidate pipeline. Isomorphic Labs, an AI-first drug design and development company, today announced it has raised $600 ...